Doxycycline pre-operatively — Competitive Intelligence Brief

Doxycycline pre-operatively (Doxycycline pre-operatively) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease / Surgical Prophylaxis.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease / Surgical Prophylaxis Small molecule

Target snapshot

Doxycycline pre-operatively (Doxycycline pre-operatively) — University of Pittsburgh. Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and when used pre-operatively, reduces surgical site infection risk through antimicrobial prophylaxis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Doxycycline pre-operatively TARGET	Doxycycline pre-operatively	University of Pittsburgh	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Amikacin (Inhalation)	Amikacin (Inhalation)	The University of Queensland	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Amikacin Injection	Amikacin Injection	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Doxycycline Tablets	Doxycycline Tablets	Yaounde Central Hospital	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Neomycin Oral Product	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Doxycycline Hyclate Enteric-Coated Capsules	Doxycycline Hyclate Enteric-Coated Capsules	The Third Xiangya Hospital of Central South University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class